Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder leading to progressive paralysis and death within 2-5 years after diagnosis. Sporadic cases (SALS) comprise approximately 90% of cases with the remaining 10% familial (FALS) caused by mutations in approximately 27 genes. The vast heterogeneity seen in age and location of disease onset, rate of progression, and duration of disease has been linked with genetic and environmental influences in both SALS and FALS cases. Increased ALS incidence clusters in Guam, southern France, and Maryland have been linked with exposure to Betamethylamino-L-alanine (BMAA), a nonproteinogenic amino acid produced by cyanobacteria, dinoflaggelates, and diatoms. We embryonically exposed zebrafish, Danio rerio, (transgenically overexpressing a FALS-causing SOD1-G93R mutation) to BMAA to investigate early motor neuron outgrowth in larvae and endurance and fatigability in 5-month adults. SOD1-G93R zebrafish showed decreased embryonic nerve length with increased BMAA dose, a phenotypic change mirrored in 5-month performance measures of weaker swimming and increased fatigability. In contrast, transgenic fish overexpressing wildtype SOD1 were resistant to phenotypic changes, indicating a potential neuroprotective function of healthy SOD1. We show that the etiology of genetic ALS animal models can be influenced by environmental exposures, and that embryonic toxin exposures can result in changes to both early and adult measures. We demonstrate that zebrafish can be a robust model for investigating causes of ALS heterogeneity. Establishing these links between developmental and adult ALS-like symptoms in the zebrafish increases the power of this model for toxicological and drug screens.
although this varies by ethnicity and geography (Caller et al., 2012) . There are approximately 30 000 U.S. Americans living with the disease and 5000 new cases diagnosed in the United States each year (Pasinelli et al., 2006) . The only FDA approved drug used to treat ALS is Riluzole, which only extends patient life by a few months (Bensimon et al., 1994) . However, many patients chose not to use Riluzole, because it does not improve ALS symptoms but leads to many adverse effects including nausea, vomiting, weakness, tachycardia, somnolence, headache, dizziness, vertigo, pain, parasthesia, and alterations in liver function tests (Stewart et al., 2001) .
Genetically, approximately 10% of ALS cases are familial ALS (FALS) (Kiernan et al., 2011) . The genetics of FALS cases are very complex, with hundreds of different mutations on 27 Mendelian genes linked to ALS in human patients (Guerreiro et al., 2015) . The other 90% of cases, which cannot be traced to a heritable mechanism, are described as sporadic (SALS) (Brooks, 1994) , and there is no clinically distinguishing characteristic between the 2 forms of the disease except an earlier mean age of onset for FALS patients with high penetrance mutations (Andersen and Al-Chalabi, 2011; Testa et al., 2004) . Phenotypically, ALS cases differ in the location of onset, rate and pattern of progression, the relative levels of degeneration among upper and lower motoneurons (Simon et al., 2014) , age of onset, and disease duration (Swinnen and Robberecht, 2014) . This huge phenotypic variation in both SALS and FALS indicates that gene-environmental interactions during development and growth play a role in the etiology of ALS (Bradley et al., 2013) and the determination of phenotypic variations (Trojsi et al., 2013) .
A suite of environmental neurotoxicants has been associated with the development of ALS, with epidemiological, clinical, and experimental evidence indicating that early developmental exposures to neurotoxins can have consequences for neurotoxicity later in life (Fox et al., 2012) . A recent study by Roy et al. (2012) showed that brief embryonic exposure of zebrafish to strychnine results in adult neurobehavioral defects in swimming speed and diving behaviors. Alterations in serum microRNAs patterns in SALS parallel those seen in young asymptomatic FALS mutation carriers and in clinical FALS patients, independent of the specific genetic defect itself (Freischmidt et al., 2014) , part of an increasing body of evidence that the development of ALS is a multi-step process, similar in etiology to cancer, where a genetic defect can lead to several outcomes depending on subsequent environmental triggers (AlChalabi et al., 2014) . This need for multiple steps in disease progression would account for adult onset (even among patients with SALS), pleiotropy of some ALS genes, and spread of symptoms from a focal point that reaches the final level of cumulative steps . The current understanding is that ALS is part of a spectrum with other neurodegenerative diseases, and that they are the product of the combination of genetics, environmental factors, and metabolism (Zufiria et al., 2016) .
Harmful Cyanobacterial Blooms (HABs) are increasing worldwide due to changing climate (Erdner et al., 2008; Hudnell, 2008; Merel et al., 2013) , and although acute toxic reactions to HABs are well known (nausea, vomiting, skin irritation, hepatotoxicity, neurotoxicity) (Hilborn et al., 2014) , the long-term impacts to exposed individuals are still undetermined, as are the potential interactions between genetic susceptibility and exposure. Exposure to repeated cyanobacterial blooms has been associated with an increased risk of ALS in New Hampshire (10-25-fold increase) (Caller et al., 2009; Torbick et al., 2014) and Southern France (Masseret et al., 2013) . One cyanobacterial neurotoxin associated with the development of ALS is Betamethylamino-L-alanine (BMAA), a nonproteinogenic amino acid produced by cyanobacteria, diatoms (Jiang et al., 2014) , and dinoflaggelates . In Guam in the 1940s-1950s, the native Chamorro people exhibited a very high incidence (50-100Â the world average ALS incidence) of ALS/Parkinsonism dementia complex, an ALS-Plus Syndrome (Koerner, 1952) . Cycad seeds in Guam were a dietary staple for the Chamorro population and for wild pigs and flying foxes, which in turn made up a large portion of the Chamorro diet. It was later determined that the BMAA was produced by cyanobacteria living in symbiosis with the cycad roots, and translocated to the seed. Biomagnification of the BMAA in the cycad seeds and animals feeding on them led to a biomagnification of BMAA in the Chamorro people (Banack and Cox, 2003) , with BMAA exposure being the only statistical correlate to their extremely high incidence of ALS (Reed et al., 1987) . Latency periods between Guam residency and ALS symptom development as long as 34 years have been seen among Chamorro immigrants (Garruto et al., 1980) , indicating that early exposures to BMAA may correlate with ALS development later in life.
Although the correlation between BMAA ingestion and increased ALS incidence is the most well studied in Guam, it is by no means restricted to that area of the world. A 2009 study found residents of Enfield New Hampshire living around the adjoining lakes Crystal lake and Lake Mascoma, which exhibit frequent high levels of cyanobacterial blooms, have a 10-20Â greater incidence of ALS than the general population (Caller et al., 2009) . In Qatar, cyanobacteria may make up to 56% of the desert crust that forms during dry seasons. A 2009 study of ALS incidence among U.S. veterans found those serving in the gulf during 1990-1991 had a significantly increased risk of developing ALS. Exposure to BMAA via cyanobacterial dust was likely heightened for Gulf War veterans by vehicular disturbance of the cyanobacterial crust (Cox et al., 2009) . A 2013 study showed that individuals living around Thao Lagoon, France had a significantly increased incidence of ALS that may be related to the high amounts of BMAA bioaccumulating in shellfish caught in the area and/or to aerosolization of BMAA off the lagoon due to high winds (Masseret et al., 2013) . A 2013 study of ALS patients in Annapolis Maryland linked their disease to the frequent consumption of blue crab, containing high levels of BMAA, caught in the Chesapeake Bay (Field et al., 2013) . Critically, a recent experimental study has shown that chronic dietary exposure to BMAA for 140d led to Neurofibrillary tangles and b-amyloid plaques in vervet monkeys (Cox et al., 2016) , indicating the potential for widespread neurological outcomes in exposed human populations.
There is presently no LD 50 or NOAEL for BMAA in either terrestrial or aquatic environments (Merel et al., 2013) , and the vast majority of BMAA exposure studies have only reported amount of BMAA per gram of plant or animal tissue. One report, however, has measured water-borne BMAA specifically in Nebraska freshwater public lakes and reservoirs with active HABs, and has found concentrations ranging from 1.8 to 24.5 mg/l (AlSammak et al., 2014). Pathological late-onset neurodegeneration is increasingly being seen as beginning early in development, and therefore investigating phenotypic linkages between development and preclinical disease measures is vital to understanding eventual pathogenesis (Kovacs et al., 2014) .
Exposing an animal to a particular neurotoxin may result in acute and/or chronic neurological defects. Determining whether these are truly involved in a neurodegenerative disease like ALS, however, is much harder to measure. We see the use of genetic animal models of ALS as a "sensitized" background on which to test the impact of toxin exposure on known timeframes of disease progression. Approximately 20% of FALS cases are due to mutations in the ubiquitously expressed Cu/Zn superoxide dismutase (SOD1) gene (Rosen et al., 1993; Siddique et al., 1991) . To date, over 200 mutations within the 153 aa SOD1 protein have been found to be associated with FALS (https://ghr. nlm.nih.gov/gene/SOD1#conditions; last accessed January 30, 2017). Since the discovery of mutations in SOD1 in ALS patients, dozens of animal models with human ALS-linked mutations have been developed, including mice (Gurney et al., 1994) and zebrafish (Ramesh et al., 2010) . A zebrafish ALS model has been developed carrying transgenes containing the endogenous zebrafish sod1 promoter and sod1 gene, with the 93rd amino acid mutated from glycine to arginine, a highly conserved amino acid often mutated in human ALS (Ramesh et al., 2010) . These fish exhibit many features of ALS, including larval and adult neuromuscular junction (NMJ) defects, decreased adult swimming endurance, and eventual age-dependent loss of motor neurons, paralysis, and death. We have therefore tested the impacts of environmentally-relevant doses of BMAA (0, 2.5, 5, 10, and 25 mg/l) on embryonic neurodevelopmental and early adult neurodegenerative phenotypes in these transgenic SOD1-ALS-zebrafish. Comparing phenotypic outcomes between genetic and genetic/environmental treatments can provide a more direct measure of how toxins may influence known neurological disease pathways, allowing us to distinguish between acute toxicities that are not involved in the disease course and those that are amplified due to the combination of genes and the environment. Here, we report genetic-environmental interactions in early neurodevelopmental alterations and on functional changes in adult-onset presymptomatic motor function in SOD1-G93R mutant ALS-zebrafish (Ramesh et al., 2010) exposed embryonically to BMAA.
MATERIALS AND METHODS
Animals. Adult zebrafish were maintained at the University of Maine zebrafish facility according to the Institutional Animal Care and Use Committee (IACUC) standards. Fertilized eggs for 30-72 hours postfertilization (hpf) experiments were collected at one cell stage before the start of experiments and raised in egg water (60 mg/l Instant Ocean Sea Salts) with 0.0003% methylene blue at 28.5 C. Transgenic embryos were subjected to 37 C heat shock for 2 h at 24 hpf for colocalization experiments or 6 hpf for nerve length experiments and sorted for their transgene by fluorescence. Adult fish used in the long-term BMAA study were collected as embryos and exposed to 5 BMAA doses for the first 5 days of life. Fertilized eggs for adult experiments were collected at one cell stage before the start of experiments and raised in egg water (60 mg/l Instant Ocean Sea Salts) with 0.0003% methylene blue at 28.5 C for 5 days. They were subjected to 37 C heat shock for 2 h at 24 hpf for transgenic sorting. At 5 days, they were placed in tanks at the University of Maine zebrafish facility and maintained according to IACUC standards until removed for spinning task experiments at 5 months.
Transgenic animals. Transgenic fish strains were donated by Dr Christine Beattie at Ohio State University. Their generation is described (Ramesh et al., 2010) . To sort for fluorescence, animals were heat shocked at 24 hpf (for 72 hpf and long-term experiments) or 6 hpf (for 30-h experiments). Heat shock was performed in a Techne thermocycler with 4 embryos per PCR tube. Heat shock consisted of a cycle of 30 min at 23 C followed by a cycle of 30 min at 37 C, repeated once. Embryos and larvae were screened for dsRed expression using a Zeiss screening microscope or Night Sea fluorescence adaptor on an Olympus SZ61.
BMAA exposure. A stock solution of 10 mg/ml BMAA (L-BMAA hydrochloride, Sigma) in DI water was diluted to 2.5, 5, 10, and 25 mg/l with egg water. Embryos were exposed after collection until euthanization. Egg water containing BMAA was changed daily.
Staining of 30 hpf embryos. Embryos were euthanized at 30 hpf with 300 mg/l Tricaine and fixed in 4% paraformaldehyde overnight at 4 C. Fixed embryos were then washed 6Â, for 10 min with 1Â PBS and blocked for 2 h at room temperature in 2% BSA, 0.5%, (increased to 1% in transgenic experiments) Triton-X 100 and 0.05% DMSO before incubation with the SV2 primary antibody ( Staining of 72 hpf embryos. Embyros treated for 72 hpf analysis had egg water changed every day. Larvae were euthanized at 72 hpf with 300 mg/l Tricaine and fixed in 4% paraformaldehyde overnight at 4 C. Fixed embryos were then permeabilized by successive incubations of DI water for 5 min, ice-cold acetone at À20 C for 60 min, DI water for 5 min. Larvae were washed 3Â for 10 min with PBST (1-2% TritonX-100, 1Â PBS) then incubated in PBDT buffer (1% DMSO, 1% BSA, 1-2% TritonX-100, 1Â PBS), with 5% normal goat serum (in later experiments PBDT buffer was replaced with Block Buffer [2% BSA, 1% Triton-X 100, 0.05% DMSO]) for 60 min followed by incubation with Alexa 647-conjugated a-BTX (1:100; Molecular Probes) for 60 min at room temperature. Then larvae were washed 3Â for 10 min with PBST. Larvae were incubated with primary mouse monoclonal anti-SV2 antibody (1:50) at 4 C overnight, then washed 6Â for 10 min with PBST and incubated in Alexa-488 conjugated goat antimouse antibody (1:400) overnight at 4 C. Then larvae were washed 4Â, 10 min in PBST, then incubated in DAPI (1:100) for 10 min. Embryos were washed 1Â with PBST for 10 min then mounted. In later experiments, staining quality was increased by agitating larvae during washes using VWR Multimix 13916-822, and by increasing SV2 and Alexa-488 goat anti-mouse antibody incubation period to 7 days.
Imaging and image analysis. Fluorescent images of embryos were taken using confocal microscopy on an Olympus FV-1000 with a 20Â objective. All embryos and larvae were flat mounted using Dako Fluorescent Mounting Media (Dako). 30 hpf nerve length analysis was performed using the FIJI simple neurite tracer on the 10 nerves on each side of the body wall beginning at the end of the yolk sac extension and continuing towards the superior end (Supplementary Figure  1) . NMJ colocalization (Supplementary Figure 2) in 72 hpf fish was analyzed using FIJI software. Images with aberrant background staining of the neural tube were cropped and a 5-chevron portion of each larva was used for analysis. The Pearson's Correlation Coefficient was calculated by FIJI between presynaptic SV2 Alexa-488 and postsynaptic a-BTX Alexa-647 staining.
Spinning task. To assess 5-month-old adult zebrafish endurance we followed a previously established protocol for assessing adult zebrafish motoneuron function (Blazina et al., 2013) . We amended the protocol to account for the relative smaller size and weaker swimming ability of our 5-month-old fish compared with the !8-month fish assessed by Blazina et al. (2013) . We lowered the rpm of the stir bar in our tests to accommodate the slower swimming speed of our younger fish. Fish were individually tested in a 1 L beaker containing 800 ml of Umaine zebrafish facility water heated to 27.5 C. The beaker was surrounded by cardboard to avoid external visual interference and increased fear, and zebrafish were allowed to acclimate to the beaker for at least 2 min before testing began. Three tests were performed in which the zebrafish was monitored and timed as it swam against a current generated by a 9 Â 50 mm stir bar at 120 rpm.
The stir bar and timer were stopped at the point when the fish was no longer able to swim against the current and lost its swimming orientation in the beaker.
Statistics. All statistics for nerve length and colocalization analysis were performed using analysis of variance (ANOVA) (JMP, Version 11. SAS Institute Inc., Cary, North Carolina, 1989 . Linear regressions for swimming endurance and fatigability were performed using JMP. FIJI simple neurite tracer length was taken for 10 nerves per fish per side. Two-way ANOVA and Dunnetts multiple comparison tests were used to determine differences between control (0) and all treatments. Differences between treatment groups were considered significant if P < .05.
RESULTS

BMAA Dose-Wise Experiments across Genotypes and Developmental Stages
Experiments were performed on a zebrafish ALS transgenic model and paired wild type (WT) transgenic control. The transgenic models, TG-zsod1 WT and TG-zsod1 G93R (Ramesh et al., 2010) , overexpress zebrafish WT Sod1 and mutant ALS-linked Sod1-G93R, respectively. We used these models to examine 2 early ALS-linked neurodevelopmental phenotypes in the zebrafish embryos and larvae: 30 hpf motor nerve length and 72 hpf NMJ colocalization. We also examined adult ALS behavioral phenotypes (swimming endurance and fatigability) in the 5-month adult zebrafish. As nontransgenic controls, we examined embryonic and larval phenotypes in AB control zebrafish, and adult phenotypes in the nontransgenic siblings of our 5-month transgenic zebrafish. Due to limitations in our transgenic fish facilities we were not able to age to adulthood fish exposed to 10 or 25 mg/l BMAA.
Altered 30 hpf Nerve Development as an Early Phenotypic Effect
Previous research (Ramesh et al., 2010) has detected the presence of an early neurological phenotype (11 days postfertilization [dpf] reduction of NMJ pre-and postsynaptic colocalization) for transgenic TG-zsod1 G93R compared with TG-zsod1 WT zebrafish. Zebrafish embryos have significantly shortened nerves at 30 hpf when transiently overexpressing ALS-causing mutant human proteins SOD1 G93A (Lemmens et al., 2007) , A4V (Lemmens et al., 2007) , and G37R (Lemmens et al., 2007) , TDP-43 G348C (Armstrong and Drapeau, 2013; Kabashi et al., 2010; Vaccaro et al., 2012) , A315T (Kabashi et al., 2010) , and A382T (Kabashi et al., 2010) , and FUS R521H (Vaccaro et al., 2012) . This has not, however, been reported in the transgenic TG-zsod1 G93R model. We sought to determine whether BMAA exposure could trigger detectable changes in nerve length at 30 hpf in the transgenic embryos. We treated TG-zsod1 G93R embryos, AB embryos, and TG-zsod1 WT embryos with 5 doses of BMAA (0, 2.5, 5.0, 10.0, and 25.0 mg/l) from the 1-cell fertilized egg stage until they were euthanized at 30 hpf, and measured motor neuron length (Supplementary Figure 1) within each genotype across the spectrum of BMAA doses and between genotypes at each BMAA dose. For AB embryos, there was a significant reduction in mean nerve length compared with controls at all doses of BMAA above 5 mg/l ( Figure 1A) . Nerve length for TG-zsod1 G93R fish was significantly lengthened with exposure to 2.5 mg/l and significantly shortened at 10 mg/l BMAA ( Figure 1B) , while nerve length in the TG-zsod1 WT fish was unaffected by any BMAA exposure ( Figure 1C ). This indicates that the genetic insult of TG-zsod1 G93R overexpression results in a bi-modal threshold for nerve alterations. Both TG-zsod1 WT and TG-zsod1 G93R embryos had significantly shorter motor neurons than AB controls (data not shown), likely due to differing genetic backgrounds between the AB and the Tg fish lines. We found that Tg-WT fish have significantly longer nerves than Tg-G93R at all BMAA doses except at 2.5 mg/l (Figure 1D ), where the G93R fish showed a significantly increased nerve length ( Figure 1B) . Overall, we have established 30 hpf mean nerve length in TGzsod1 G93R as a new early phenotype effected by BMAA exposure in this transgenic zebrafish model of ALS.
Altered NMJ Colocalization as an Early Phenotypic Effect
Previous research has established that a reduction in colocalization at the 11 dpf NMJ was correlated with late stage ALS-like phenotypes including loss of endurance, motor neuron loss, sporadic paralysis, and early death (Ramesh et al., 2010) . NMJ colocalization values are scored using Pearson's correlation coefficient, a statistic measuring correlation of localization of pixels between 2 fluorescent channels (perfect colocalization ¼ 1, perfect unrelatedness ¼ 0). We examined NMJ colocalization (Supplementary Figure 2) at 72hpf to determine whether an earlier time-point could be affected by BMAA exposure. For AB fish, all doses of BMAA resulted in higher NMJ colocalization values than controls (Figure 2A ). For TG-zsod1 G93R embryos ( Figure  2B ), there is a significant increase in NMJ colocalization at 10 and 25 mg/l BMAA compared with the controls (0 mg/l BMAA). This dose-dependent pattern of changes in 72hpf colocalization was distinct from the dose-dependent pattern of BMAAinduced changes in 30 hpf nerve length in the TG-zsod1 G93R ( Figure 1B) , where a low dose (2.5 mg/l) resulted in longer nerves and a higher dose (10 mg/l) resulted in decreased nerve length. For TG-zsod1 WT, ( Figure 2C ) BMAA has no effect on NMJ colocalization, consistent with our finding that BMAA exposure had no effect on 30hpf nerve length ( Figure 1C ). There were significant differences in NMJ colocalization between G93R and WT genotypes at the higher doses of 10 (P ¼ .0010) and 25 mg/l (P ¼ .0126) BMAA ( Figure 2D ), with G93R having higher Pearson's values at both doses. Ramesh et al. (2010) reported that the TG-zsod1 G93R fish develops ALS-like motor symptoms in adulthood. These symptoms include loss of swimming endurance (12 months) and paralysis, motor neuron loss, and early death (>16 months). We explored how early embryonic BMAA exposure could affect endurance in the adult zebrafish at presymptomatic stages. TG-zsod1 G93R and TG-zsod1 WT embryos (and their nontransgenic siblings, referred to here as NTG-zsod1 G93R and NTG-zsod1 WT, respectively) were exposed to 0, 2.5, or 5 mg/l BMAA for the first 5 days of life and were then raised under standard conditions in the University of Maine zebrafish facility. At 5 months of age, we quantified their endurance and fatigability using a modified version of the spinning task protocol (Blazina et al., 2013) .
BMAA Exposure and Establishing Loss of Endurance Symptoms in the 5-Month-Old Zebrafish
To quantify endurance, 10 fish were selected from each treatment group and timed in 3 consecutive trials as they swam against a current generated in a 1000 ml beaker containing 800 ml water with a stir bar spinning at 120 rpm. Each trial was deemed over when the fish lost its orientation while attempting to swim against the current. There is a significant reduction in endurance in the 5-month-old TG-zsod1 G93R fish exposed to the highest dose (5 mg/l BMAA) ( Figure 3A ) and a significant increase in endurance in TG-zsod1 WT ( Figure 3B ) fish compared with controls. At 0 and 5 mg/l BMAA exposure, there are no significant differences in swimming ability between TG-zsod1 WT and TGzsod1 G93R 5 month fish, while WT fish swim significantly better than G93R fish after having been exposed to 5 mg/l BMAA during the first week of life ( Figure 3C ). Linear regression shows that there are significant trends in which increasing BMAA exposure causes an increase in swimming ability among TG-zsod1 WT fish and at the same time causes a significant decrease in swimming ability among TG-zsod1 G93R fish ( Figure 3D ). This indicates that although there is no detectable difference in swimming endurance between the transgenic fish based on genotype alone (in the absence of BMAA exposure) at this presymptomatic stage, the interaction between BMAA and genotype is able to drive a significant difference in this phenotype with increasing dose.
Swimming endurance was also examined for the nontransgenic siblings at each BMAA dose tested and we found that NTG-zsod1 WT had improved swimming when exposed to 2.5 or 5 mg/l BMAA compared with controls, while NTG-zsod1 G93R showed no difference with BMAA exposure compared with controls ( Figure 3E ). This may be due to the fact that the WT strain had poorer dsRED expression and was more difficult to sort during embryo development, and therefore some of the TG animals may have mistakenly been labeled nonTG. The lack of any change in the NTG-zsod1-G93R siblings indicates that the changes in endurance in the TG-zsod1-G93R animals are not driven solely by the application of BMAA, but rather is from the negative interaction of SOD1-G93R and BMAA.
Establishing Fatigability Symptoms in the 5-Month-Old Zebrafish
Increased fatigability is seen in human ALS patients, with one report showing that over the course of 25 min of exercise, voluntary and tetanic force declined more sharply in ALS with controls (each P < .001). B, Nerve length within TG-zsod1 G93R is significantly increased at 2.5 mg/l and significantly shortened at 10 mg/l BMAA compared with controls (each P < .001). C, Nerve length within TG-zsod1 WT embryos is unaffected by the BMAA doses tested (all P > .11). D, There are significant differences in overall nerve length between G93R and WT genotypes at each dose. Tg-G93R embryos have significantly shorter nerves at all doses except at 2.5 mg/l, where they are significantly longer than Tg-WT. Asterix (*) indicates significant difference between G93R and WT within each dose (P < .001 for all comparisons). patients than in controls, indicating increased fatigue (Sharma et al., 1995) . Fatigability has not previously been reported as a potential ALS-like phenotype in the zebrafish, however Ramesh et al. did report that Tg-G93R fish that failed in the swim test did not recover well (Ramesh et al., 2010) . To determine fatigability, we examined how performance changed across 3 consecutive swimming trials for each fish. We found that TG-zsod1 G93R zebrafish ( Figure 4A ) show significant fatigue after early exposure to 0 or 5 mg/l BMAA while TG-zsod1 WT fish ( Figure 4B ) show no significant fatigue regardless of early BMAA exposure. This recapitulates the trend seen in TGzsod1 G93R 30hpf mean nerve length. This may also indicate that 30 hpf mean nerve length in the TG-zsod1 G93A and TGzsod1 WT zebrafish is a predictor of these adult ALS-like phenotypes. Because this phenotype is present only in the TG-zsod1 G93R model, we believe this is a phenotype that can be used to monitor ALS-like symptoms in the zebrafish at the preclinical stage in future toxicological studies.
Overexpression of WT SOD1 Provides Neuroprotection
If overexpression of Sod1WT was independent of any BMAA induced phenotypic changes, we would expect to see identical results in the AB and TG-zsod1 WT models. NMJ colocalization and nerve growth in the embryonic/larval AB zebrafish was altered by exposure to BMAA. However, these BMAA dosedependent changes in phenotype were not recapitulated in the TG-zsod1 WT model. This apparent neuroprotective function of WT SOD1, may also be seen when comparing the 5-month swim endurance between TG-zsod1 WT zebrafish and their nontransgenic siblings. Endurance in the 5-month TG-zsod1 WT zebrafish was actually improved after early 5 mg/l BMAA dose. This increase in endurance is only seen in TG-zsod1 WT zebrafish. There is no change in endurance over doses tested in the nontransgenic siblings TG-zsod1 G93R, and TG-zsod1 G93R endurance decreases with BMAA dose. This overcompensation for early BMAA exposure may be mediated by SOD1 WT overexpression.
DISCUSSION
Developmental plasticity, whereby one genotype gives rise to multiple phenotypic outcomes in response to environmental and/or genetic disruptions, is proposed to be the mechanism by which early developmental defects can lead to late-onset disease states or lead to altered disease course over time (Barker, 2004; Coppede et al., 2006; Sasaki and Kishi, 2013; Vaiserman, 2011) . Early defects in neural circuitry have been found to be associated with late-onset neurological disorders, including both cognitive and degenerative diseases (Fox et al., 2012; Kovacs et al., 2014; Tang et al., 2014) . Recently, key genes required for human neuronal differentiation during fetal development were also identified as genes involved in late-onset neurodegeneration, highlighting the mechanistic link between FIG. 2. NMJ colocalization in 72 hpf transgenic larvae is significantly between treatments and genotypes. Asterix (*) indicates significantly different than control (0 mg/l BMAA) according to Dunnetts Multiple Comparison. A, NMJ colocalization in AB embryos is significantly higher with all BMAA doses compared with control (all P < 0.0001). B, NMJ colocalization within TG-zsod1 G93R larvae significantly increases at 10 mg/l (P ¼ .0027) and 25 mg/l BMAA (P ¼ .0185) BMAA. C, NMJ colocalization within TG-zsod1 WT larvae is unaffected by BMAA dose (P ¼ .5587). D, NMJ colocalization differs significantly between genotypes depending on BMAA dose. TG-zsod1 G93R embryos have significantly higher colocalization than TG-zsod1 WT larvae at 10 mg/l (P ¼ .0010) and 25 mg/l (P ¼ .0261) BMAA.
pathways necessary for early neuronal development and lateonset disease (Iglesias et al., 2013; Zhang et al., 2013) , and of the utility of examining early embryonic defects as surrogates and precursors for adult clinical-stage neurodegenerative diseases. Potentially, mutations in genes crucial to early neuronal differentiation make neurons more susceptible to environmental disruptions, leading to late-onset disease (Modgil et al., 2014; Zhang et al., 2013) . Early toxicological environmental exposures can also result in epigenetic changes that impact gene expression patterns later in life, leading to a later-onset disease state (Reamon-Buettner et al., 2008) .
One environmental neurotoxin linked through epidemiological studies to ALS is BMAA. BMAA exposure through ingestion (Banack and Murch., 2009) or inhalation (Cox et al., 2009 ) has been associated with an increased prevalence of ALS in exposed human populations. BMAA is a nonproteinogenic amino acid. It is an analog of glutamate, capable of binding postsynaptic NMDA and AMPA/kainite glutamate receptors (Vyas and Weiss, FIG. 3 . Swimming endurance at 5 months is significantly altered by BMAA dose within and between genotypes. A, Endurance within TG-zsod1 G93R fish is significantly reduced after early exposure to 5 mg/l BMAA (P ¼ .019). B, Endurance within TG-zsod1 WT fish is significantly increased after early BMAA exposure to 5 mg/l (P ¼ .0010). C, Endurance between TG-zsod1 G93R and TG-zsod1 WT is significantly altered after early exposure to 5 mg/l BMAA, with TG-zsod1 WT having significantly better endurance (* indicates significant difference between genotypes at each treatment dose). D, Linear regression indicates a significant decrease (P ¼ .0006, y ¼ À0.8267x þ 8.7946, R 2 ¼ 0.351) in endurance in TG-zsod1 G93R with BMAA dose and a significant increase (P ¼ .0028, y ¼ 5556x þ 6.1462, R 2 ¼ 0.277) in endurance in TG-zsod1 WT with BMAA dose. E, There is no significant difference between NTG-zsod1 G93R sibs exposed to BMAA and controls, while NTG-zsod1-WT sibs show increased swimming at 2.5 and 5 mg/l BMAA exposure compared with controls (* indicate significant difference from 0 BMAA control within each genotype).
2009). It is known to be produced by cyanobacteria, diatoms (Jiang et al., 2014) , and dinoflaggelates . It is prolifically produced worldwide in freshwater (Al-Sammak et al., 2014; Esterhuizen and Downing, 2008; Metcalf et al., 2008) , estuarine (Cervantes Cianca et al., 2012) , and saltwater environments (Brand et al., 2010) . BMAA can exist freely as an amino acid or become incorporated into protein (Karamyan and Speth, 2008; Metcalf et al., 2008) and has been found in plant and animal tissue at various trophic levels. In vitro, BMAA has been shown to incorporate into human proteins in place of L-serine (Dunlop et al., 2013) . The incorporation of nonproteinogenic amino acids into protein is not unique to BMAA, it has also been shown to occur with other nonproteinogenic amino acids: canavanine and L-Dopa (Rodgers and Shiozawa, 2008) . This phenomenon occurs when nonproteinogenic amino acids are mistakenly bound to an amino tRNA synthetase in place of an animo acid structural analog (Dunlop et al., 2013) . Since they were first reported in 1883, toxin producing cyanobacterial blooms have been increasing in incidence, duration, and intensity largely because of declining water quality worldwide (Carmichael, 2008) . Therefore, the impact of climate and eutrophication, which contribute directly to increased incidence FIG. 4 . Fatigability in 5-month-old zebrafish differs increases in Tg-zsod1-G93R but not in Tg-zsod1-WT fish. A-C, Linear regression reveals that there is are significant increases in fatigability as the no. of swim challenges (trials) increase in TG-zsod1 G93R zebrafish exposed embryonically to 0 and 5 mg/l BMAA. A 0 -C 0 , Linear regression reveals that TG-zsod1 WT zebrafish do not become significantly fatigued regardless of BMAA dose tested.
of bloom formation, on cyanobacterial blooms is of critical importance to the exposure of human populations to BMAA. Increasing nutrient enrichment (eutrophication) of water bodies associated with human industrial and agricultural methods favors (Paerl and Paul, 2012) HABs and is correlated with increased cyanobacterial growth (Vahtera et al., 2007) . Because eutrophication is primarily caused by human activities, incidence of toxic cyanobacterial blooms is essentially the same worldwide, with some increases in toxic blooms in areas of warmer climates. In addition to eutrophication, climate change (global warming) is suspected to favor cyanobacterial growth by leading to increases in metabolism, growth rates, and bloom formation (Paerl and Paul, 2012) . According to the International Panel on Climate Change (IPCC, 2014), global temperatures are expected to rise by as much as 2.5-7.8 C by 2100. The prokaryotic cyanobacteria flourish at higher temperatures than their eukaryotic planktonic algae competitors. Therefore, a global increase in temperature may select for cyanobacterial growth and proliferation (Butterwick et al., 2004) . Drosophila larvae fed BMAA show delayed and progressive neurotoxicity in adults (Zhou et al., 2010) , and BMAA has high placental transfer into the brain of embryonic rodents through exposure to pregnant females (Karlsson et al., 2009a) , with neonatal exposure resulting in permanent changes in postnatal neural development and long-term adult cognitive impairments (Dawson et al., 1998; Karlsson et al., 2009b Karlsson et al., , 2011 Karlsson et al., , 2013 . BMAA is excreted in milk during lactation , a key route of exposure for neonates during a particularly sensitive timepoint (Karlsson et al., 2009a (Karlsson et al., ,b, 2011 (Karlsson et al., , 2012 . These examples indicate that early human exposure to BMAA may have drastic consequences on susceptible individuals. We find that early exposure to BMAA results in embryonic nerve development defects in a dose-dependent manner in mutant overexpressing G93R-SOD1 fish, and that these early defects are reflected in adult presymptomatic swimming capability. Interestingly, we find that there is no impact on these measures in fish overexpressing the unmutated WT SOD1, and that in some measures the WT-SOD1 fish actually improve, implying a possible protective role against neurodegeneration. Our results show that early exposure to BMAA has genotype-specific effects on early neurodevelopment and on adult motor function.
Our studies of gene-environment interactions have identified new influences on the development of ALS-like phenotypes, and have expanded on our understanding of previously established early indicators of ALS and human-like presymptomatic stage ALS symptoms in the zebrafish. These phenotypes are extremely heterogeneous, similar to the wide range of phenotypes seen in SALS and FALS patients (Kiernan et al., 2011) . Interestingly, these embryonic alterations are not linearly dosedependent, but rather show more complex bell-shaped/biphasic or multi-phasic response. This is not surprising, as the combination of genetics and toxins could potentially result in multiple molecular and biochemical interactions. In fact, developmental exposure of zebrafish to methymercury has been shown to result in biphasic behavioral alterations, with midrange doses having greater effects than low or higher doses (Weber, 2006) . Similarly, embryonic exposure to lead (Pb) results in multiphasic dose by age-specific GABAergic gene expression and GABA protein level responses (Wirbisky et al., 2014) . These bi-and multi-phasic responses to biological plasticity, also described as a hormetic response, have been extensively described in neurodevelopmental and neurological disease experimentation (Calabrese, 2008; Calabrese et al., 2010; Calabrese and Mattson, 2011) . These responses overall are generalizable and independent of the biological model, the endpoint being measured, or the chemical class being used, and have been observed for chemicals, metals, herbicides and radiation exposures (Calabrese, 2013) . These responses are reflected in our 30 and 72 hpf phenotypic measures, with medium doses having a larger impact than low or high doses.
These results were interesting to us because although one might expect a simple linear effect of dose, the bell shape of the responses indicates that there are indeed gene-toxin specific interactions that have previously been unreported. These sorts of nonlinear toxicological effects can be seen with other multiple-insult acute toxicity studies, but to our understanding, this is the first study looking at the impact over long-term development of an adult-onset disease. This study highlights the importance of investigating low-dose exposures in the context of genetic mutations, as the potential for compensation interactions is important. Our results in this initial study will allow us to look for biochemical/molecular pathways at the impacted doses that might point to mechanisms of function.
Toxicity and drug studies in the zebrafish are cost effective, fast, and easily regulated, particularly during early development, making drug and toxicity studies in zebrafish genetic disease models ideal (Chakravarthy et al., 2014) . By establishing the correlation of earlier biomarkers for ALS with late stage ALS human-like phenotypes in the zebrafish, we can improve the potential for drug and toxicity screening. It has been proposed that measures of eventual functional impairment can be a more complex response to early toxin exposure than acute mortality or structural alterations (Samson et al., 2001) . We have identified phenotypic changes at earlier developmental time points than have previously been reported for both NMJ alterations and for adult swimming endurance, and we have established 30 hpf mean nerve length reduction and increased fatigability in the 5-month-old zebrafish as new disease phenotypes in the TGzsod1 G93R and TG-zsod1 WT models. TG-zsod1 WT overexpression results in stable phenotypes after BMAA exposure when compared with AB phenotypes, which show dose-dependent phenotypic changes. Critically, we have found that early exposure to BMAA results in a decrease in swimming endurance and an increase in fatigability in 5-month-old TG-zsod1 G93R fish, and that these behavioral adult defects are reflected early on in embryonic development. This study contributes to our understanding of neurodegeneration as a multi-hit, long-term progression of disease that may begin with alterations in neural circuitry early in life (Tartaglione et al., 2016) .
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
ACKNOWLEDGMENTS
We thank Mark Nilan for maintenance of zebrafish colonies. We thank Dr Clarissa Henry and Dr Julie Gosse for critical reading of the article. We thank Michelle Goodey for technical assistance.
FUNDING
Funding was supplied by the University of Maine (startup funds for R.S.) and from a gift from the WaterWheel Foundation.
